Canadian model Linda Evangelista filed a R746 million lawsuit against ZELTIQ Aesthetics for a cosmetic procedure she claims left her “brutally disfigured”, announced via an Instagram post on Saturday 25 September.
LINDA EVANGELISTA CLAIMS SHE WAS ‘BRUTALLY DISFIGURED’
Linda Evangelista was one of the biggest names on runways and magazine covers in the 1990s. In an Instagram post on 22 September she opened up about a painful fat reduction treatment she had done about five years ago.
The Canadian model claims a CoolSculpting procedure by ZELTIQ Aesthetics did the opposite of what it promised and left her “brutally disfigured” which turned her into a recluse.
“To my followers who have wondered why I have not been working while my peers’ careers have been thriving, the reason is that I was brutally disfigured by Zeltiq’s CoolSculpting procedure which did the opposite of what it promised,” she wrote on Instagram.
She then explained that she developed Paradoxical Adipose Hyperplasia (PAH). This is a rare adverse effect of CoolSculpting which results in swelling of the area that was treated. CoolSculpting uses cooling to damage and destroy fat cells to reduce the amount of fat in the treated area.
“PAH has not only destroyed my livelihood, it has sent me into a cycle of deep depression, profound sadness, and the lowest depths of self-loathing. In the process, I have become a recluse,” she continued.
ALSO READ: See why Meghan Markle is all about ‘girl power’ on Time Magazine cover
LINDA FILES R746 MILLION LAWSUIT AGAINST ZELTIQ AESTHETICS
Linda Evangelista posted a letter from her lawyer on Instagram revealing that she is filing a products liability lawsuit against the ZELTIQ Aesthetics as a result of their Coolsculpting system. The lawsuit reportedly amounts to $50 million (R746 million). The letter states that she is doing this not just for herself, but for others who have also been “injured and ignored” by ZELTIQ.
“It is telling that ZELTIQ disclosed the risk of paradoxical adipose hyperplasia (‘PAH’) to its investors in its SEC filings years before disclosing that risk in any of its aggressive direct-to-consumer marketing material,” read the letter.
“Zeltiq’s 2012 10-K warned its investors of possible ‘additional liability from claims related to known rare side effects such as late-onset pain, subcutaneous induration, hernia, and paradoxical hyperplasia’ and that its product liability insurance ‘may not be adequate to cover [ZELTIQ] against potential liability,” continued the letter.
The letter also pointed out that the marketing material of the company failed to include the risks of the procedure until after Linda’s procedure.
“Remarkably, ZELTIQ’s marketing material and the CoolSculpting website failed to mention the risk of PAH until after Ms. Evangelista underwent the procedures. ZELTIQ failed to even include any general warning on CoolSculpting’s main homepage until February 2019,” according to the letter.
ALSO READ: ‘No shame in my game’: Cheeky Chrissy Teigen’s face-off with fat [watch]